Frontline Brentuximab Vedotin as Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9 / 10
页数：2
相关论文
共 50 条
  • [31] Where Does Brentuximab Vedotin Fit into the Management of Patients with Hodgkin Lymphoma?
    Goyal, Sagun D.
    Bartlett, Nancy L.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2012, 7 (03) : 179 - 185
  • [32] Where Does Brentuximab Vedotin Fit into the Management of Patients with Hodgkin Lymphoma?
    Sagun D. Goyal
    Nancy L. Bartlett
    Current Hematologic Malignancy Reports, 2012, 7 : 179 - 185
  • [33] Real World Experience with Sequential Brentuximab Vedotin Plus AVD Chemotherapy As Frontline Therapy for Older Patients with Classical Hodgkin Lymphoma: A Multicenter Retrospective Study
    Perez, Ariel Perez
    Abdel-Razeq, Nayef
    Al Sagheer, Tiba
    Nahas, George
    Sandoval-Sus, Jose
    Alfonso, Manny
    Silva, Carlos
    Kareem, Syeda Saba
    Tobon, Katherine
    Rosenthal, Allison C.
    Ansell, Stephen M.
    Linhares, Yuliya P. L.
    Moustafa, Muhamad Alhaj
    Saeed, Hayder
    BLOOD, 2024, 144 : 1672 - 1673
  • [34] Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin
    Zinzani, Pier Luigi
    Derenzini, Enrico
    Pellegrini, Cinzia
    Celli, Monica
    Broccoli, Alessandro
    Argnani, Lisa
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (05) : 681 - 683
  • [35] A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination as Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma
    Massaro, Fulvio
    Maerevoet, Marie
    Meuleman, Nathalie
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S250 - S250
  • [36] Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma
    Friedman, Judah
    Lee, Hun Ju
    Ho, Linda
    Flinn, Ian W.
    BLOOD, 2019, 134
  • [37] A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination As Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma
    Massaro, Fulvio
    Meuleman, Nathalie
    Bron, Dominique
    Maerevoet, Marie
    BLOOD, 2020, 136
  • [38] Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
    Wu, Hung-Bo
    Yeh, Shyh-An
    Chen, Huei-Yung
    CASE REPORTS IN HEMATOLOGY, 2013, 2013
  • [39] Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma
    Babashov, V.
    Begen, M. A.
    Mangel, J.
    Zaric, G. S.
    CURRENT ONCOLOGY, 2017, 24 (01) : E6 - E14
  • [40] Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma
    Steiner, Raphael E.
    Hwang, Steven R.
    Khurana, Arushi
    Habermann, Thomas M.
    Epperla, Narendranath
    Annunzio, Kaitlin
    Allen, Pamela Blair
    Baird, Katelin
    Paulino, Darina
    Alderuccio, Juan Pablo
    Lossos, Izidore S.
    David, Kevin
    Evens, Andrew M.
    Pandya, Karan
    Bair, Steven M.
    Kamdar, Manali
    Aqeel, Sheeba Ba
    Torka, Pallawi
    Lynch, Ryan
    Smith, Stephen
    Feng, Lei
    Noorani, Mansoor
    Ahmed, Sairah
    Nair, Ranjit
    Vega, Francisco
    Wu, Susan
    Fang, Penny
    Pinnix, Chelsea C.
    Gunther, Jillian R.
    Dabaja, Bouthaina S.
    Lee, Hun J.
    BLOOD ADVANCES, 2023, 7 (24) : 7485 - 7493
12345